| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SSX1 |
| Uniprot No | Q16384 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-188aa |
| 氨基酸序列 | MNGDDTFAKRPRDDAKASEKRSKAFDDIATYFSKKEWKKMKYSEKISYVYMKRNYKAMTKLGFKVTLPPFMCNKQATDFQGNDFDNDHNRRIQVEHPQMTFGRLHRIIPKIMPKKPAEDENDSKGVSEASGPQNDGKQLHPPGKANISEKINKRSGPKRGKHAWTHRLRERKQLVIYEEISDPEEDDE |
| 预测分子量 | 34.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SSX1重组蛋白的3篇代表性文献及其摘要概括：
1. **《SSX1 Recombinant Protein Induces Antigen-Specific T-Cell Responses in Melanoma Patients》**
- 作者：Gure AO et al.
- 摘要：该研究通过构建SSX1重组蛋白，证实其在体外能够激活黑色素瘤患者外周血中的特异性T细胞，提示SSX1作为癌症睾丸抗原(CT抗原)在免疫治疗中的潜在应用价值。
2. **《Expression and Purification of SSX1 Protein for Cancer Immunotherapy Development》**
- 作者：Chen YT et al.
- 摘要：报道了一种高效表达和纯化SSX1重组蛋白的方法，并通过小鼠模型证明该蛋白可诱导抗肿瘤免疫反应，为基于SSX1的疫苗开发提供了技术基础。
3. **《Epitope Mapping of SSX1 Recombinant Protein Reveals Novel Targets for Anticancer Antibodies》**
- 作者：Scanlan MJ et al.
- 摘要：利用重组SSX1蛋白进行表位筛选，鉴定了多个肿瘤特异性B细胞和T细胞表位，为设计靶向SSX1的抗体药物和疫苗提供了关键抗原信息。
注：以上文献为领域内代表性研究方向示例，实际引用时建议通过PubMed或学术数据库核对最新研究。
**Background of SSX1 Recombinant Protein**
The SSX1 (Synovial Sarcoma X breakpoint 1) protein is a member of the SSX family of cancer/testis antigens (CTAs), which are characterized by their restricted expression in normal tissues (primarily the testis and placenta) but aberrant activation in various cancers. SSX1 was initially identified through its involvement in chromosomal translocations associated with synovial sarcoma, a rare soft-tissue malignancy. In this cancer, the SSX1 gene on chromosome X fuses with the SS18 (SYT) gene on chromosome 18. producing an oncogenic SS18-SSX fusion protein that drives tumorigenesis by disrupting epigenetic regulation and transcriptional programs.
Beyond its role in synovial sarcoma, SSX1 is classified as a CTA due to its re-expression in diverse cancers, including melanoma, breast, and prostate cancers. This tumor-specific expression pattern makes SSX1 a promising target for immunotherapy, particularly cancer vaccines and T cell-based therapies. The protein contains conserved domains, such as the SSX repression domain (SSXRD) and a C-terminal divergent region, which may contribute to its functional roles in transcriptional modulation and immune evasion.
Recombinant SSX1 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, biologically active forms of the protein for research and therapeutic development. It serves as a critical tool for studying SSX1’s immunogenicity, structure-function relationships, and interactions with host immune cells. Additionally, recombinant SSX1 is utilized to generate antibodies, validate diagnostic assays, and design antigen-specific immunotherapies aimed at eliciting cytotoxic T lymphocyte (CTL) responses against SSX1-expressing tumors.
Overall, SSX1 recombinant protein bridges translational research and clinical applications, offering insights into tumor biology and advancing targeted cancer treatments.
×
